Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus FEXOFENADINE HYDROCHLORIDE HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus FEXOFENADINE HYDROCHLORIDE HIVES.
DRIXORAL vs FEXOFENADINE HYDROCHLORIDE HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Fexofenadine hydrochloride is a selective peripheral H1-receptor antagonist. It blocks the action of histamine at the H1 receptor, preventing histamine-mediated symptoms such as itching, sneezing, rhinorrhea, and urticaria.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
60 mg orally twice daily or 180 mg orally once daily
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Terminal elimination half-life is 14.4 hours (range 11–17 hours) in healthy adults. Clinically, this supports twice-daily dosing for symptomatic relief.
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Approximately 95% of the dose is excreted unchanged in feces (80%) and urine (15%). Fexofenadine undergoes minimal hepatic metabolism (<5%).
Category C
Category A/B
Antihistamine/Decongestant
Antihistamine